Microfluidics: A focus on improved cancer targeted drug delivery systems
Pharmaceutical science aims to localize the pharmacological activity of the drug at the site of action. Targeted drug delivery systems can directly deliver the payload to the desired site of action without undesired interaction with normal cells. This is especially important for anticancer drugs to...
Gespeichert in:
Veröffentlicht in: | Journal of controlled release 2013-12, Vol.172 (3), p.1065-1074 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1074 |
---|---|
container_issue | 3 |
container_start_page | 1065 |
container_title | Journal of controlled release |
container_volume | 172 |
creator | Khan, Ikram Ullah Serra, Christophe A. Anton, Nicolas Vandamme, Thierry |
description | Pharmaceutical science aims to localize the pharmacological activity of the drug at the site of action. Targeted drug delivery systems can directly deliver the payload to the desired site of action without undesired interaction with normal cells. This is especially important for anticancer drugs to avoid side effects and improve therapeutic response and patient compliance. Number of targeted drug delivery systems for anticancer drugs are in market and many more are in research phase. Most of the methods so far used suffer from poor drug loading, variation in composition, attachment of targeting ligands to carriers, and in vivo and in vitro cellular uptake in cancer cell. Recently microfluidic techniques are gaining attention from researchers and formulation scientists due to the ability of having a better control over the above said parameters not to mention saving cost, material, time and the possibility offered to synthesize different system morphologies from nano to microscale. This article reviews the recent advances in the design of various targeted systems obtained through microfluidics and to some extent addresses challenges and hurdles faced during cancer cell treatment.
[Display omitted] |
doi_str_mv | 10.1016/j.jconrel.2013.07.028 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1516743297</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168365913004380</els_id><sourcerecordid>1516743297</sourcerecordid><originalsourceid>FETCH-LOGICAL-c422t-aee6d41ad6f60e0014ce893b49d1a24055d5ef390071498cf3a060a792bb1d5e3</originalsourceid><addsrcrecordid>eNqFkEtP3DAQgK2qqCy0PwHIsZeE8TvmUiEEpRJVD8DZ8tqTlVfJBuxkpf33NdqFK6fRaL55fYScUWgoUHW5btZ-3CTsGwaUN6AbYO0XsqCt5rUwRn4li8K1NVfSHJOTnNcAILnQ38gx44ZzycSC3P-NPo1dP8cQfb6qrqtu9HOuxk0Vh5c0bjFU3m08pmpyaYVTyUOaV1XAPm4x7aq8yxMO-Ts56lyf8cchnpLnu9unm_v64d_vPzfXD7UXjE21Q1RBUBdUpwABqPDYGr4UJlDHBEgZJHbcAGgqTOs77kCB04Ytl7SU-Cn5uZ9bjnudMU92iNlj37sNjnO2VFKlBWdGf44KpbgWQoqCyj1aZOScsLMvKQ4u7SwF--bbru3Bt33zbUHb4rv0nR9WzMsBw0fXu-ACXOyBzo3WrVLM9vmxTJDlda25hkL82hNYrG0jJpt9xGI8xIR-smGMnxzxH-LDnH0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1466374454</pqid></control><display><type>article</type><title>Microfluidics: A focus on improved cancer targeted drug delivery systems</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Khan, Ikram Ullah ; Serra, Christophe A. ; Anton, Nicolas ; Vandamme, Thierry</creator><creatorcontrib>Khan, Ikram Ullah ; Serra, Christophe A. ; Anton, Nicolas ; Vandamme, Thierry</creatorcontrib><description>Pharmaceutical science aims to localize the pharmacological activity of the drug at the site of action. Targeted drug delivery systems can directly deliver the payload to the desired site of action without undesired interaction with normal cells. This is especially important for anticancer drugs to avoid side effects and improve therapeutic response and patient compliance. Number of targeted drug delivery systems for anticancer drugs are in market and many more are in research phase. Most of the methods so far used suffer from poor drug loading, variation in composition, attachment of targeting ligands to carriers, and in vivo and in vitro cellular uptake in cancer cell. Recently microfluidic techniques are gaining attention from researchers and formulation scientists due to the ability of having a better control over the above said parameters not to mention saving cost, material, time and the possibility offered to synthesize different system morphologies from nano to microscale. This article reviews the recent advances in the design of various targeted systems obtained through microfluidics and to some extent addresses challenges and hurdles faced during cancer cell treatment.
[Display omitted]</description><identifier>ISSN: 0168-3659</identifier><identifier>EISSN: 1873-4995</identifier><identifier>DOI: 10.1016/j.jconrel.2013.07.028</identifier><identifier>PMID: 23933524</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Active and passive targeting ; adverse effects ; Animals ; antineoplastic agents ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - therapeutic use ; Cancer therapy ; cost effectiveness ; Drug Carriers - chemistry ; drug delivery systems ; Drug Delivery Systems - instrumentation ; Drug Delivery Systems - methods ; Equipment Design ; Humans ; markets ; Microchannel ; Microfluidic Analytical Techniques - instrumentation ; Microfluidic Analytical Techniques - methods ; Microfluidics ; Nanocarriers ; Nanostructures - chemistry ; Neoplasms - drug therapy ; patient compliance ; Targeted drug delivery</subject><ispartof>Journal of controlled release, 2013-12, Vol.172 (3), p.1065-1074</ispartof><rights>2013 Elsevier B.V.</rights><rights>2013.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c422t-aee6d41ad6f60e0014ce893b49d1a24055d5ef390071498cf3a060a792bb1d5e3</citedby><cites>FETCH-LOGICAL-c422t-aee6d41ad6f60e0014ce893b49d1a24055d5ef390071498cf3a060a792bb1d5e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jconrel.2013.07.028$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,27928,27929,45999</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23933524$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Khan, Ikram Ullah</creatorcontrib><creatorcontrib>Serra, Christophe A.</creatorcontrib><creatorcontrib>Anton, Nicolas</creatorcontrib><creatorcontrib>Vandamme, Thierry</creatorcontrib><title>Microfluidics: A focus on improved cancer targeted drug delivery systems</title><title>Journal of controlled release</title><addtitle>J Control Release</addtitle><description>Pharmaceutical science aims to localize the pharmacological activity of the drug at the site of action. Targeted drug delivery systems can directly deliver the payload to the desired site of action without undesired interaction with normal cells. This is especially important for anticancer drugs to avoid side effects and improve therapeutic response and patient compliance. Number of targeted drug delivery systems for anticancer drugs are in market and many more are in research phase. Most of the methods so far used suffer from poor drug loading, variation in composition, attachment of targeting ligands to carriers, and in vivo and in vitro cellular uptake in cancer cell. Recently microfluidic techniques are gaining attention from researchers and formulation scientists due to the ability of having a better control over the above said parameters not to mention saving cost, material, time and the possibility offered to synthesize different system morphologies from nano to microscale. This article reviews the recent advances in the design of various targeted systems obtained through microfluidics and to some extent addresses challenges and hurdles faced during cancer cell treatment.
[Display omitted]</description><subject>Active and passive targeting</subject><subject>adverse effects</subject><subject>Animals</subject><subject>antineoplastic agents</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Cancer therapy</subject><subject>cost effectiveness</subject><subject>Drug Carriers - chemistry</subject><subject>drug delivery systems</subject><subject>Drug Delivery Systems - instrumentation</subject><subject>Drug Delivery Systems - methods</subject><subject>Equipment Design</subject><subject>Humans</subject><subject>markets</subject><subject>Microchannel</subject><subject>Microfluidic Analytical Techniques - instrumentation</subject><subject>Microfluidic Analytical Techniques - methods</subject><subject>Microfluidics</subject><subject>Nanocarriers</subject><subject>Nanostructures - chemistry</subject><subject>Neoplasms - drug therapy</subject><subject>patient compliance</subject><subject>Targeted drug delivery</subject><issn>0168-3659</issn><issn>1873-4995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEtP3DAQgK2qqCy0PwHIsZeE8TvmUiEEpRJVD8DZ8tqTlVfJBuxkpf33NdqFK6fRaL55fYScUWgoUHW5btZ-3CTsGwaUN6AbYO0XsqCt5rUwRn4li8K1NVfSHJOTnNcAILnQ38gx44ZzycSC3P-NPo1dP8cQfb6qrqtu9HOuxk0Vh5c0bjFU3m08pmpyaYVTyUOaV1XAPm4x7aq8yxMO-Ts56lyf8cchnpLnu9unm_v64d_vPzfXD7UXjE21Q1RBUBdUpwABqPDYGr4UJlDHBEgZJHbcAGgqTOs77kCB04Ytl7SU-Cn5uZ9bjnudMU92iNlj37sNjnO2VFKlBWdGf44KpbgWQoqCyj1aZOScsLMvKQ4u7SwF--bbru3Bt33zbUHb4rv0nR9WzMsBw0fXu-ACXOyBzo3WrVLM9vmxTJDlda25hkL82hNYrG0jJpt9xGI8xIR-smGMnxzxH-LDnH0</recordid><startdate>20131228</startdate><enddate>20131228</enddate><creator>Khan, Ikram Ullah</creator><creator>Serra, Christophe A.</creator><creator>Anton, Nicolas</creator><creator>Vandamme, Thierry</creator><general>Elsevier B.V</general><scope>FBQ</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>20131228</creationdate><title>Microfluidics: A focus on improved cancer targeted drug delivery systems</title><author>Khan, Ikram Ullah ; Serra, Christophe A. ; Anton, Nicolas ; Vandamme, Thierry</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c422t-aee6d41ad6f60e0014ce893b49d1a24055d5ef390071498cf3a060a792bb1d5e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Active and passive targeting</topic><topic>adverse effects</topic><topic>Animals</topic><topic>antineoplastic agents</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Cancer therapy</topic><topic>cost effectiveness</topic><topic>Drug Carriers - chemistry</topic><topic>drug delivery systems</topic><topic>Drug Delivery Systems - instrumentation</topic><topic>Drug Delivery Systems - methods</topic><topic>Equipment Design</topic><topic>Humans</topic><topic>markets</topic><topic>Microchannel</topic><topic>Microfluidic Analytical Techniques - instrumentation</topic><topic>Microfluidic Analytical Techniques - methods</topic><topic>Microfluidics</topic><topic>Nanocarriers</topic><topic>Nanostructures - chemistry</topic><topic>Neoplasms - drug therapy</topic><topic>patient compliance</topic><topic>Targeted drug delivery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Khan, Ikram Ullah</creatorcontrib><creatorcontrib>Serra, Christophe A.</creatorcontrib><creatorcontrib>Anton, Nicolas</creatorcontrib><creatorcontrib>Vandamme, Thierry</creatorcontrib><collection>AGRIS</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Journal of controlled release</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Khan, Ikram Ullah</au><au>Serra, Christophe A.</au><au>Anton, Nicolas</au><au>Vandamme, Thierry</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Microfluidics: A focus on improved cancer targeted drug delivery systems</atitle><jtitle>Journal of controlled release</jtitle><addtitle>J Control Release</addtitle><date>2013-12-28</date><risdate>2013</risdate><volume>172</volume><issue>3</issue><spage>1065</spage><epage>1074</epage><pages>1065-1074</pages><issn>0168-3659</issn><eissn>1873-4995</eissn><abstract>Pharmaceutical science aims to localize the pharmacological activity of the drug at the site of action. Targeted drug delivery systems can directly deliver the payload to the desired site of action without undesired interaction with normal cells. This is especially important for anticancer drugs to avoid side effects and improve therapeutic response and patient compliance. Number of targeted drug delivery systems for anticancer drugs are in market and many more are in research phase. Most of the methods so far used suffer from poor drug loading, variation in composition, attachment of targeting ligands to carriers, and in vivo and in vitro cellular uptake in cancer cell. Recently microfluidic techniques are gaining attention from researchers and formulation scientists due to the ability of having a better control over the above said parameters not to mention saving cost, material, time and the possibility offered to synthesize different system morphologies from nano to microscale. This article reviews the recent advances in the design of various targeted systems obtained through microfluidics and to some extent addresses challenges and hurdles faced during cancer cell treatment.
[Display omitted]</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>23933524</pmid><doi>10.1016/j.jconrel.2013.07.028</doi><tpages>10</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0168-3659 |
ispartof | Journal of controlled release, 2013-12, Vol.172 (3), p.1065-1074 |
issn | 0168-3659 1873-4995 |
language | eng |
recordid | cdi_proquest_miscellaneous_1516743297 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | Active and passive targeting adverse effects Animals antineoplastic agents Antineoplastic Agents - administration & dosage Antineoplastic Agents - therapeutic use Cancer therapy cost effectiveness Drug Carriers - chemistry drug delivery systems Drug Delivery Systems - instrumentation Drug Delivery Systems - methods Equipment Design Humans markets Microchannel Microfluidic Analytical Techniques - instrumentation Microfluidic Analytical Techniques - methods Microfluidics Nanocarriers Nanostructures - chemistry Neoplasms - drug therapy patient compliance Targeted drug delivery |
title | Microfluidics: A focus on improved cancer targeted drug delivery systems |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T13%3A49%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Microfluidics:%20A%20focus%20on%20improved%20cancer%20targeted%20drug%20delivery%20systems&rft.jtitle=Journal%20of%20controlled%20release&rft.au=Khan,%20Ikram%20Ullah&rft.date=2013-12-28&rft.volume=172&rft.issue=3&rft.spage=1065&rft.epage=1074&rft.pages=1065-1074&rft.issn=0168-3659&rft.eissn=1873-4995&rft_id=info:doi/10.1016/j.jconrel.2013.07.028&rft_dat=%3Cproquest_cross%3E1516743297%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1466374454&rft_id=info:pmid/23933524&rft_els_id=S0168365913004380&rfr_iscdi=true |